Expression and clinical significance of heparanase in neuroblastoma.
BACKGROUND
Previous studies indicate that heparanase (HPA), an endoglycosidase involved in tumor angiogenesis and metastasis, is up-regulated in a variety of malignancies. However, the expression of HPA in neuroblastoma (NB), one of the most common extra cranial solid tumors in children, remains unknown. This study was undertaken to explore the expression and clinical significance of HPA in NB.


METHODS
Immunohistochemical staining was applied to detect the expression of HPA in 42 cases of NB. The relationships among HPA expression, international neuroblastoma staging system (INSS) stages, histopathological classification, and postoperative survival of the NB patients were analyzed.


RESULTS
The expression rate of HPA in NB was 61.9% (26/42), mainly in the cytoplasm of neuroblastoma cells. The expression rates of stage 1-2, stage 3-4 and stage 4S were 35.7%, 80.0% and 62.5%, respectively. The differences between stage 1-2 and stage 3-4 were significant (P<0.01). The expression of HPA was significantly higher in the NB cases that had one of the histopathological factors: age more than 1 year (P<0.01), poorer differentiation (P<0.01), and higher mitosis karyorrhexis index (P<0.01). The survival time of HPA-negative patients was significantly longer than that of HPA-positive patients (P<0.05).


CONCLUSIONS
Although these results indicate that heparanase might be correlated with development and progression of NB, a larger series of patients with a longer follow-up are probably needed to strengthen its role in assessment of NB prognosis.
Zheng
Li-Duan
LD
Department of Pathology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Tong
Qiang-Song
QS
Tang
Shao-Tao
ST
Du
Zhi-Yong
ZY
Liu
Yuan
Y
Jiang
Guo-Song
GS
Cai
Jia-Bin
JB
D000310:Adrenal Gland Neoplasms / Q000201:enzymology*; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D005260:Female; D005966:Glucuronidase / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D008297:Male; D008479:Mediastinal Neoplasms / Q000201:enzymology; D009447:Neuroblastoma / Q000201:enzymology* / Q000401:mortality; D012186:Retroperitoneal Neoplasms / Q000201:enzymology; D000099175:Heparanase
D005966:Glucuronidase; D000099175:Heparanase
Br J Cancer. 2002 Apr 22;86(8):1270-5
11953884
Int J Cancer. 1999 Oct 29;83(3):424-31
10495437
Lancet. 1994 Sep 24;344(8926):869-70
7916408
J Natl Cancer Inst. 2004 Aug 18;96(16):1219-30
15316057
Ann Oncol. 2003 Oct;14(10):1505-10
14504050
Int J Cancer. 2006 Apr 1;118(7):1609-17
16217746
Oncologist. 2003;8(3):278-92
12773750
Cancer. 1999 Jul 15;86(2):364-72
10421273
Lab Invest. 2003 May;83(5):613-22
12746471
Int J Cancer. 2001 Sep 20;95(5):295-301
11494228
Nat Med. 1999 Jul;5(7):793-802
10395325
Cancer Res. 2004 Jun 1;64(11):3928-33
15173004
Mol Cancer Ther. 2004 Sep;3(9):1069-77
15367701
World J Pediatr. 2008 Feb;4(1):58-62
18402255
Cancer Sci. 2007 Apr;98(4):535-40
17284253
J Pediatr Hematol Oncol. 1999 May-Jun;21(3):190-7
10363851
Cancer Res. 2006 Feb 1;66(3):1455-63
16452201
Pathol Int. 2004 Aug;54(8):556-63
15260846
J Surg Oncol. 2004 Sep 15;87(4):174-81
15334632
Int J Biochem Cell Biol. 2006;38(12):2018-39
16901744
J Cancer Res Clin Oncol. 2005 Apr;131(4):229-37
15625607
Clin Cancer Res. 2005 Nov 15;11(22):7995-8005
16299228